Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 30;16(1):150.
doi: 10.1186/s12886-016-0327-9.

Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term

Affiliations

Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term

Yaoyao Sun et al. BMC Ophthalmol. .

Abstract

Background: To present a comprehensive approach for the management of patients with neovascular glaucoma (NVG) aiming to preserve visual function and complement pan-retinal photocoagulation (PRP) by anti-vascular endothelial growth factor (anti-VEGF) treatment and anti-glaucoma surgery.

Methods: This study includes a prospective, interventional case series. A process flow chart for NVG management was designed. Totally 50 patients (51 eyes) with NVG were included. Of these, 43 patients (44 eyes) completed the treatment process. Patients were divided into central retinal vein occlusion (CRVO) and proliferative diabetic retinopathy (PDR) groups according to their original diagnosis. Intraocular pressure (IOP), visual function, and the status of iris and angle neovascularization were recorded before and after treatment.

Results: Patients were followed up for 6-30 months (mean 12.2 months). The IOP of all 44 patients was effectively controlled and was significantly less after treatment (16.68 ± 4.69 mmHg) than before treatment (42.59 ± 9.44 mmHg, P < 0.05). Thirty-nine eyes displayed controlled IOP (≤21 mmHg) after treatment. Visual acuity improved, to some extent, in 32 eyes (72.9 %), and 12 eyes (27.3 %) had a visual acuity better than 0.1. There was no significant difference in IOP between the PDR and CRVO groups at the end of follow-up (P = 0.8657), but the visual acuity in the PDR group was much better than that in the CRVO group (P = 0.0079).

Conclusions: A comprehensive therapy for NVG can effectively control IOP and preserve visual function in patients by anti-VEGF injection and anti-glaucoma surgery.

Keywords: Anti-VEGF therapy; Anti-glaucoma surgery; Neovascular glaucoma; Pan-retinal photocoagulation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A chart of the neovascular glaucoma treatment process
Fig. 2
Fig. 2
Visual acuity before and after treatment. A total of 32 (72.9 %) eyes showed improved vision, to various degrees. Of these, 12 (27.3 %) had a visual acuity ≥0.1, 9 (20.5 %) remained unchanged, and 3 (6.8 %) became worse. Of the NLP eyes at the time of diagnosis, 3 of 5 had re-acquired their visual acuity at the end of treatment and had visual acuity values of 0.05, 0.04, and 0.01
Fig. 3
Fig. 3
Typical examination results of a 53-year-old man diagnosed with CRVO combined with NVG in the right eye. His physical examination was demonstrated in a and b. c showed the clinical finding after a trabeculectomy. At the patient’s follow-ups at 12 (e) and 24 (f) months after discharge, his visual acuity was 0.03 and his IOP was 18 mmHg in the right eye. No leakage was observed in FFA (d)
Fig. 4
Fig. 4
Typical examination results of a 46-year-old woman diagnosed with PDR combined with NVG. a Demonstrated in the physical examination. The cornea returned to clear after a trabeculectomy (b, d). PRP was carried out (e). At the end of the follow-up, at 10 months after the patient’s discharge, her visual acuity was 0.05 and her IOP was 20 mmHg in the left eye (c). No leakage was observed in FFA leakage (f)

Similar articles

Cited by

References

    1. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusaka S, Tano Y. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115(9):1571–80. doi: 10.1016/j.ophtha.2008.02.026. - DOI - PubMed
    1. Simha A, Braganza A, Abraham L, Samuel P, Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2013;10:CD007920. - PMC - PubMed
    1. SooHoo JR, Seibold LK, Kahook MY. Recent advances in the management of neovascular glaucoma. Semin Ophthalmol. 2013;28(3):165–72. doi: 10.3109/08820538.2012.730103. - DOI - PubMed
    1. Konareva-Kostianeva M. Neovascular glaucoma. Folia Med (Plovdiv) 2005;47(2):5–11. - PubMed
    1. Park SC, Su D, Tello C. Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. Expert Opin Biol Ther. 2012;12(12):1641–7. doi: 10.1517/14712598.2012.721772. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources